Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Affymax Inc. stock logo
AFFY
Affymax
$0.00
$0.00
$0.00
▼
$0.00
N/A7.326,994 shsN/A
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
$0.00
$0.00
▼
$0.00
N/AN/AN/AN/A
TRSBF
3SBio
$2.12
-1.5%		$2.20
$2.00
▼
$4.74
N/AN/A2,351 shs28 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Affymax Inc. stock logo
AFFY
Affymax
0.00%0.00%+50.00%+36.36%+87.50%
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
0.00%0.00%0.00%0.00%0.00%
TRSBF
3SBio
-1.48%-1.48%-1.48%-25.68%-49.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Affymax Inc. stock logo
AFFY
Affymax
$0.00
$0.00
$0.00
▼
$0.00
N/A7.326,994 shsN/A
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
$0.00
$0.00
▼
$0.00
N/AN/AN/AN/A
TRSBF
3SBio
$2.12
-1.5%		$2.20
$2.00
▼
$4.74
N/AN/A2,351 shs28 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Affymax Inc. stock logo
AFFY
Affymax
0.00%0.00%+50.00%+36.36%+87.50%
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
0.00%0.00%0.00%0.00%0.00%
TRSBF
3SBio
-1.48%-1.48%-1.48%-25.68%-49.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADOIF
Adocia
0.00
N/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
0.00
N/AN/AN/A
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADOIF
Adocia
N/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/A
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADOIF
Adocia
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A8/26/2026 (Estimated)

Latest CRXM, TRSBF, ADOIF, and AFFY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/26/2026N/A
TRSBF
3SBio
$0.0942N/AN/AN/A$689.32 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ADOIF
Adocia
N/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/A
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ADOIF
Adocia
N/A
Affymax Inc. stock logo
AFFY
Affymax
N/A
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
N/A
TRSBF
3SBio
N/A

Insider Ownership

CompanyInsider Ownership
ADOIF
Adocia
N/A
Affymax Inc. stock logo
AFFY
Affymax
1.55%
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
49.80%
TRSBF
3SBio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ADOIF
Adocia
97N/AN/ANot Optionable
Affymax Inc. stock logo
AFFY
Affymax
4N/AN/ANot Optionable
Cardium Therapeutics Inc. stock logo
CRXM
Cardium Therapeutics
3N/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable

Recent News About These Companies

3SBio Inc. (OTCMKTS:TRSBF) Short Interest Up 142.1% in July
July 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30926582
3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue Mandate
June 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-sets-june-2026-agm-to-approve-dividend-new-auditor-and-share-issue-mandate?utm_source=marketbeat.com&utm_medium=referral
3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off Dividend
April 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-calls-extraordinary-meeting-to-approve-mandi-spin-off-dividend?utm_source=marketbeat.com&utm_medium=referral
3SBio Proposes HKD 0.25 Final Dividend for 2025 Financial Year
March 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/3sbio-proposes-hkd-0-25-final-dividend-for-2025-financial-year?utm_source=marketbeat.com&utm_medium=referral
Chinese Biotech Stocks Surge After 3SBio's $6 Billion Licensing Deal With Pfizer -- Update
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/chinese-biotech-stocks-surge-after-3sbio-s-6-billion-licensing-deal-with-pfizer-update-22768f03
Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/biotech-company-3sbio-s-shares-surge-after-6-billion-licensing-deal-with-pfizer-6bf7cbed
Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion
May 20, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/pfizer-licenses-3sbio-cancer-drug-for-record-12-billion/ar-AA1F5ZDf
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
July 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cosmo-and-3sbio-announce-signing-of-license-agreement-for-winlevi-174-in-china-1031624145
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
August 26, 2021  |  finance.yahoo.comhttps://finance.yahoo.com/news/3sbio-announces-2021-interim-results-140900893.html?.tsrc=rss

Media Sentiment Over Time

Adocia OTCMKTS:ADOIF

C$8.87 0.00 (0.00%)
As of 05/12/2023

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Affymax stock logo

Affymax OTCMKTS:AFFY

$0.0015 0.00 (0.00%)
As of 08/4/2026

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Cardium Therapeutics stock logo

Cardium Therapeutics OTCMKTS:CRXM

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

3SBio OTCMKTS:TRSBF

$2.12 -0.03 (-1.48%)
As of 08/5/2026

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas